ALNYLAM PHARMACEUTICALS INC (ALNY) Stock Price, Quote, News and Overview
NASDAQ:ALNY - Nasdaq - US02043Q1076 - Common Stock - Currency: USD
ALNY Quote, Performance and Key Statistics
250.59
-0.41 (-0.16%)
The current stock price of ALNY is 250.59 USD. In the past month the price decreased by -9.05%. In the past year, price increased by 58.95%.
ALNY Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.86 | 16.12B |
Related stock screener links
About ALNY
Company Profile
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,100 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. In addition, the Company develops Cemdisiran to treat complement-mediated diseases, Belcesiran for the treatment of alpha-1 liver disease, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran, and others.
Company Info
ALNYLAM PHARMACEUTICALS INC
675 W Kendall St
Cambridge MASSACHUSETTS 02142 US
CEO: John M. Maraganore
Employees: 2100
Company Website: https://www.alnylam.com/
Investor Relations: https://investors.alnylam.com/
Phone: 16175518200
ALNYLAM PHARMACEUTICALS INC / ALNY FAQ
What is the stock price of ALNYLAM PHARMACEUTICALS INC today?
The current stock price of ALNY is 250.59 USD. The price decreased by -0.16% in the last trading session.
What is the ticker symbol for ALNYLAM PHARMACEUTICALS INC stock?
The exchange symbol of ALNYLAM PHARMACEUTICALS INC is ALNY and it is listed on the Nasdaq exchange.
On which exchange is ALNY stock listed?
ALNY stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ALNYLAM PHARMACEUTICALS INC stock?
37 analysts have analysed ALNY and the average price target is 311.37 USD. This implies a price increase of 24.26% is expected in the next year compared to the current price of 250.59. Check the ALNYLAM PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ALNYLAM PHARMACEUTICALS INC worth?
ALNYLAM PHARMACEUTICALS INC (ALNY) has a market capitalization of 32.32B USD. This makes ALNY a Large Cap stock.
How many employees does ALNYLAM PHARMACEUTICALS INC have?
ALNYLAM PHARMACEUTICALS INC (ALNY) currently has 2100 employees.
What are the support and resistance levels for ALNYLAM PHARMACEUTICALS INC (ALNY) stock?
ALNYLAM PHARMACEUTICALS INC (ALNY) has a support level at 235.56 and a resistance level at 250.73. Check the full technical report for a detailed analysis of ALNY support and resistance levels.
Is ALNYLAM PHARMACEUTICALS INC (ALNY) expected to grow?
The Revenue of ALNYLAM PHARMACEUTICALS INC (ALNY) is expected to grow by 27.01% in the next year. Check the estimates tab for more information on the ALNY EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ALNYLAM PHARMACEUTICALS INC (ALNY) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALNY, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALNY, evaluating the profitability, health, valuation and growth aspects
- ALNYLAM PHARMACEUTICALS INC (ALNY) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ALNYLAM PHARMACEUTICALS INC (ALNY) Sales and EPS estimates to see what analysts future expectations are.
- ALNYLAM PHARMACEUTICALS INC (ALNY) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ALNYLAM PHARMACEUTICALS INC (ALNY) Insider and Institutional Ownership to learn about the owners and their transactions.
- ALNYLAM PHARMACEUTICALS INC (ALNY) Stock Chart to make your own analysis
- ALNYLAM PHARMACEUTICALS INC (ALNY) Latest news and press-releases to stay up to date.
Does ALNYLAM PHARMACEUTICALS INC (ALNY) stock pay dividends?
ALNY does not pay a dividend.
When does ALNYLAM PHARMACEUTICALS INC (ALNY) report earnings?
ALNYLAM PHARMACEUTICALS INC (ALNY) will report earnings on 2025-04-30, before the market open.
What is the Price/Earnings (PE) ratio of ALNYLAM PHARMACEUTICALS INC (ALNY)?
ALNYLAM PHARMACEUTICALS INC (ALNY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.17).
What is the Short Interest ratio of ALNYLAM PHARMACEUTICALS INC (ALNY) stock?
The outstanding short interest for ALNYLAM PHARMACEUTICALS INC (ALNY) is 2.38% of its float. Check the ownership tab for more information on the ALNY short interest.
ALNY Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ALNY. When comparing the yearly performance of all stocks, ALNY is one of the better performing stocks in the market, outperforming 90.32% of all stocks.
ALNY Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ALNY. While ALNY seems to be doing ok healthwise, there are quite some concerns on its profitability.
ALNY Financial Highlights
Over the last trailing twelve months ALNY reported a non-GAAP Earnings per Share(EPS) of -2.17. The EPS increased by 39.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -6.56% | ||
| ROE | -414.62% | ||
| Debt/Equity | 15.27 |
ALNY Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to ALNY. The Buy consensus is the average rating of analysts ratings from 37 analysts.
For the next year, analysts expect an EPS growth of 22.85% and a revenue growth 27.01% for ALNY